Hiroaki Yashiro Selected Research

Enteropeptidase

1/2022	Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity.
1/2021	Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice.
10/2019	SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroaki Yashiro Research Topics

Disease

4	Fibrosis (Cirrhosis) 11/2021 - 01/2020
4	Non-alcoholic Fatty Liver Disease 11/2021 - 01/2020
3	Obesity 01/2022 - 10/2019
2	Fatty Liver 10/2021 - 04/2021
1	Hypertrophy 11/2021
1	Inflammation (Inflammations) 10/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021
1	Body Weight (Weight, Body) 10/2019
1	Insulin Resistance 10/2019
1	Liver Diseases (Liver Disease) 10/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2017
1	Hypoglycemia (Reactive Hypoglycemia) 02/2012

Drug/Important Bio-Agent (IBA)

3	EnteropeptidaseIBA 01/2022 - 10/2019
2	Triglycerides (Triacylglycerol)IBA 11/2021 - 01/2020
2	Acetyl-CoA CarboxylaseIBA 11/2021 - 01/2020
2	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 11/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2020
2	FructoseIBA 10/2021 - 04/2021
2	N- (((3S)- 6- ((4- carbamimidamidobenzoyl)oxy)- 2,3- dihydro- 1- benzofuran- 3- yl)acetyl)- L- aspartic acid hydrateIBA 01/2021 - 10/2019
2	Glucose (Dextrose)FDA LinkGeneric 10/2019 - 02/2012
1	EstersIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Biological ProductsIBA 01/2022
1	4-guanidinobenzoateIBA 01/2022
1	Coenzyme A (CoA)IBA 11/2021
1	Interleukin-22 (IL-22)IBA 10/2021
1	CollagenIBA 10/2021
1	Ethanol (Ethyl Alcohol)IBA 10/2021
1	ketohexokinaseIBA 04/2021
1	EnzymesIBA 04/2021
1	fructose-1-phosphateIBA 04/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Appetite Depressants (Anorectics)IBA 01/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Metalloproteases (Metalloproteinases)IBA 01/2020
1	Malonyl Coenzyme A (Malonyl CoA)IBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	firsocostatIBA 01/2020
1	Tissue Inhibitor of Metalloproteinase-1IBA 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Collagen Type I (Type I Collagen)IBA 01/2020
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2020
1	Essential Amino AcidsIBA 10/2019
1	LipidsIBA 10/2019
1	Alanine Transaminase (SGPT)IBA 10/2019
1	Pharmaceutical PreparationsIBA 01/2017
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2017
1	TAK-875IBA 02/2012
1	Glucagon (Glukagon)FDA Link 02/2012

Therapy/Procedure

1	Oral Administration 01/2022